Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Diageo plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Diageo plc trades at $81.18 (market cap $45.92B). The key difference: Diageo plc is far larger — about 10.2× ACADIA Pharmaceuticals Inc.'s market cap, and Diageo plc pays a 4.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DEO | |
|---|---|---|
Market Cap | $4.49B | $45.92B |
Sector | Health | Technology |
52-Week High | $28.06 | $115.33 |
52-Week Low | $20.06 | $72.47 |
Enterprise Value | $3.69B | $66.74B |
Dividend Yield | — | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Diageo (DEO) trades at $81.67, down 0.6% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 12.19% net margin and 22.29% ROE, but faces headwinds in the US spirits market. Recent news highlights CEO Dave Lewis's upcoming strategy update amid concerns over US demand and promotional pressures.
The outlook is cautious with analyst consensus leaning buy (48.65%) but significant hold ratings (43.24%). Key risks include US market weakness and shifting consumer trends, while opportunities lie in premiumization and innovation. The stock's valuation at a P/E of 18.87 appears reasonable if recovery initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
